3758 Clinical and cost-effectiveness of the UCL live well with Parkinson’s self-management toolkit—an RCT
Klinische und kosteneffektive Wirkung des UCL Live Well with Parkinson’s Self-Management-Toolkits – eine RCT
Age and Ageing · 05.02.2026 · 55 (Supplement_1)
DOI: 10.1093/ageing/afaf368.156 ↗Auf einen Blick
Bei Menschen mit Parkinson zeigte das Toolkit nach 12 Monaten keine signifikante Verbesserung der gesundheitsbezogenen Lebensqualität. Es war jedoch mit besseren Symptomen und geringeren Gesundheits- und Sozialkosten verbunden.
Fragestellung
Verbessert das UCL Live Well with Parkinson’s Self-Management-Toolkit bei Menschen mit Parkinson die gesundheitsbezogene Lebensqualität und ist es kosteneffektiv?
Methode
Einfach verblindete RCT in England; Community-dwelling Personen mit Parkinson 1:1 zu Intervention oder üblicher Versorgung; primärer Endpunkt PDQ-39 nach 12 Monaten.
Ergebnisse
346 Teilnehmende; mittleres Alter 69 Jahre, 159 (46 %) Frauen. PDQ-39: −1,03 (−3,03 bis 0,97), p = 0,31. MDS-UPDRS Teil I/II, GHQ-12, EQ-5D-5L VAS und Kosten teilweise signifikant zugunsten der Intervention.
Schlussfolgerung der Autor:innen
Das Selbstmanagement-Tool hat nach Ansicht der Autor:innen Potenzial, Parkinson-Symptome zu verbessern und eine kosteneffektive Versorgung zu unterstützen.
Kernaussagen
- Kein signifikanter Unterschied im PDQ-39 nach 12 Monaten
- Bessere Symptomwerte bei MDS-UPDRS Teil I und II
- Niedrigere Gesundheits- und Sozialkosten in der Interventionsgruppe
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Age and Ageing, online erschienen am 05.02.2026. Verfasst von K Walters und 12 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Parkinson’s disease (PD) affects 1/50 people over 65 years, with complex health and social care needs and difficulty accessing timely support. We co-designed and tested a self-management toolkit for people with PD and their carers (UCL Live Well with Parkinson’s), to improve health outcomes and healthcare needs. The toolkit contains information about symptoms, treatment, optimising wellbeing, and practical advice. The sub-sections, personalised with the help of a supporter, cover information on health and support, allow symptom reviewing/tracking, and to work towards health priorities.
Method
The clinical and cost-effectiveness were tested in a single-blind RCT in England. We randomised community-dwelling participants with PD 1:1 to the intervention or treatment-as-usual. The primary outcome was health-related quality of life (PDQ-39) at 12-months. Outcomes were analysed using linear mixed models, controlling for baseline.
Results
We recruited 346 participants between January 2022–July 2023 (mean age 69 (SD 9) years, 159 (46%) women, 321 (93%) white). Data collection was completed in August 2024 with 88% retention at 12-months. Small, but not statistically significant differences in PDQ-39 were seen for intervention participants (−1.03(−3.03 to 0.97); p = 0.31). There were significant differences in favour of the intervention arm in symptom changes on the MDS-UPDRS part I and II at 6- and 12-months (−2.19(−3.95 to −0.43) and − 2.61(−4.58 to −0.64)). We found significant differences in psychological distress (GHQ-12) (−0.87(−1.71 to −0.03)) and overall health status (EQ-5D-5L VAS) (3.87(0.32 to 7.41)) at 6-months. At 12-months, intervention group participants had significantly lower health and social care costs (mean incremental cost saving per participant -£1459(−£2903 to -£16)), inclusive of the average per-participant intervention costs of £284. There was no difference in 12-month QALYs (mean incremental QALYs 0.02(−0.01 to 0.04)) and hence dominates treatment-as-usual.
Conclusion
Our self-management tool has potential to improve PD symptoms and support cost-effective management of patients with PD.
Zitieren
APA
Walters, K., Kantilal, K., Rookes, T., Adeleke, M., Ambler, G., Gonzalez, L., Wang, J., Hunter, R., Schartau, P., Atkinson, C., Gardner, B., Davies, N., & Schrag, A. (2026). 3758 Clinical and cost-effectiveness of the UCL live well with Parkinson’s self-management toolkit—an RCT. Age and Ageing, 55(Supplement_1). https://doi.org/10.1093/ageing/afaf368.156
Vancouver
Walters K, Kantilal K, Rookes T, Adeleke M, Ambler G, Gonzalez L, et al. 3758 Clinical and cost-effectiveness of the UCL live well with Parkinson’s self-management toolkit—an RCT. Age and Ageing. 2026;55(Supplement_1). doi:10.1093/ageing/afaf368.156
BibTeX
@article{Walters2026,
author = {Walters, K and Kantilal, K and Rookes, T and Adeleke, M and Ambler, G and Gonzalez, L and Wang, J and Hunter, R and Schartau, P and Atkinson, C and Gardner, B and Davies, N and Schrag, A},
title = {3758 Clinical and cost-effectiveness of the UCL live well with Parkinson’s self-management toolkit—an RCT},
journal = {Age and Ageing},
year = {2026},
volume = {55},
number = {Supplement_1},
doi = {10.1093/ageing/afaf368.156}
}
EUVIMED